Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity

American Journal of Physiology - Endocrinology and Metabolism

Volumn 300, Issue 1, 2011, Pages

  Yarasheski, Kevin E ^a   Cade, W Todd ^a   Overton, E Turner ^a   Mondy, Kristin E ^a   Hubert, Sara ^a   Laciny, Erin ^a   Bopp, Coco ^a   Lassa Claxton, Sherry ^a   Reeds, Dominic N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease risk factors; Chronic inflammation; Diabetes; Human immunodeficiency virus 1; Metabolic complications; Physical activity

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; DRUG MECHANISM; EDEMA; FEMALE; FLUID RETENTION; GLYCEMIC CONTROL; HEART FAILURE; HEPATOBILIARY DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHYSICAL ACTIVITY; PREHYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; SIDE EFFECT; WEIGHT GAIN;

ADIPOSITY; ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PPAR GAMMA; RESISTANCE TRAINING; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 78650784868     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00468.2010     Document Type: Article

References (59)

1. Bashir A, Laciny E, Lassa-Claxton S, Yarasheski KE. Magnetic resonance imaging for quantifying regional adipose tissue in human immunodeficiency virus-infected persons with the cardiometabolic syndrome. J Cardiometab Syndr 3: 115-118, 2008.
2. Bezante GP, Briatore L, Rollando D, Maggi D, Setti M, Ghio M, Agosti S, Murdaca G, Balbi M, Barsotti A, Cordera R. Hypoadiponectinemia in lipodystrophic HIV individuals: a metabolic marker of subclinical cardiac damage. Nutr Metab Cardiovasc Dis 19: 277-282, 2009.
3. Blümer RM, van der Valk M, Ackermans M, Endert E, Serlie MJ, Reiss P, Sauerwein HP. A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy. Am J Physiol Endocrinol Metab 297: E1097-E1104, 2009.
4. Booth FW, Chakravarthy MV, Gordon SE, Spangenburg EE. Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy. J Appl Physiol 93: 3-30, 2002.
5. Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med 118: 890-898, 2005.
6. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 165: 1179-1184, 2005. (Pubitemid 40720744)
7. Cade WT, Reeds DN, Lassa-Claxton S, Davila-Roman VG, Waggoner AD, Powderly WG, Yarasheski KE. Post-exercise heart rate recovery in HIV-positive individuals on highly active antiretroviral therapy. Early indicator of cardiovascular disease? HIV Med 9: 96-100, 2008.
8. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA; Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363: 429-438, 2004.
9. Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis 195: 1754-1761, 2007.
10. Chinkes DL, Wolfe RR. Isotope Tracers in Metabolic Research: Principles and Practice of Kinetic Analysis, 2nd edition. Hoboken, NJ: John Wiley & Sons, 2005.
11. Choi AI, Li Y, Deeks SG, Grunfeld C, Volberding PA, Shlipak MG. Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons. Circulation 121: 651-658, 2010.
12. Choi JH, Banks AS, Estall JL, Kajimura S, Boström P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Blüher M, Griffin PR, Spiegelman BM. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 466: 451-456, 2010.
13. Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM; Diabetes Prevention Program Research Group. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 4: 382-393, 2008.
14. Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374: 1677-1686, 2009.
15. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 275: 41325-41332, 2000.
16. Driscoll SD, Meininger GE, Lareau MT, Dolan SE, Killilea KM, Hadigan CM, Lloyd-Jones DM, Klibanski A, Frontera WR, Grinspoon SK. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 18: 465-473, 2004.
17. Feldt T, Oette M, Kroidl A, Goebels K, Fritzen R, Kambergs J, Kappert G, Vogt C, Wettstein M, Häussinger D. Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection 34: 55-61, 2006.
18. French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, Anastos K, Augenbraun M, Cohen MH. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 51: 399-406, 2009.
19. Fritz T, Krämer DK, Karlsson HK, Galuska D, Engfeldt P, Zierath JR, Krook A. Low-intensity exercise increases skeletal muscle protein expression of PPARdelta and UCP3 in type 2 diabetic patients. Diabetes Metab Res Rev 22: 492-498, 2006.
20. Gavrila A, Hsu W, Tsiodras S, Doweiko J, Gautam S, Martin L, Moses AC, Karchmer AW, Mantzoros CS. Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 40: 745-749, 2005.
21. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, Brebbia JS, Wax MR, McNurlan MA. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163-170, 2002.
22. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 304: 411-418, 2010.
23. Grinspoon S. Use of thiazolidinediones in HIV-infected patients: what have we learned? J Infect Dis 195: 1731-1733, 2007.
24. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 85: 35-41, 2000.
25. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 140: 786-794, 2004.
26. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 39: 1423-1434, 2007. (Pubitemid 47344026)
27. Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, Mack WJ, Cohen MH, Jacobson L, Gange SJ. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 45: 1074-1081, 2007.
28. Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein S. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 59: 1899-1905, 2010.
29. Krämer DK, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J Biol Chem 282: 19313-19320, 2007.
30. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298: 1180-1188, 2007.
31. Lindegaard B, Hansen T, Hvid T, van Hall G, Plomgaard P, Ditlevsen S, Gerstoft J, Pedersen BK. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab 93: 3860-3869, 2008.
32. Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, Fu Y. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 59: 791-799, 2010.
33. Macallan DC, Baldwin C, Mandalia S, Pandol-Kaljevic V, Higgins N, Grundy A, Moyle GJ. Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone. HIV Clin Trials 9: 254-268, 2008.
34. Mallon PW, Sedwell R, Rogers G, Nolan D, Unemori P, Hoy J, Samaras K, Kelleher A, Emery S, Cooper DA, Carr A; Rosey Investigators. Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction. J Infect Dis 198: 1794-1803, 2008.
35. Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, Chisholm D, Samaras K, Emery S, Kelleher A, Cooper DA, Carr A; SAMA Investigators. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 191: 1686-1696, 2005.
36. Martínez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis 22: 28-34, 2009.
37. Marwick TH, Hordern MD, Miller T, Chyun DA, Bertoni AG, Blumenthal RS, Philippides G, Rocchini A; Council on Clinical Cardiology, American Heart Association Exercise, Cardiac Rehabilitation, andPrevention Committee; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; Council on Nutrition, Physical Activity, and Metabolism; Interdisciplinary Council on Quality of Care and Outcomes Research. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119: 3244-3262, 2009.
38. Matthews DR, Hosker JP, Rudneski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
39. Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 20: 2043-2050, 2006.
40. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, Schouten JT, Fielding RA, Basar MT, Grinspoon S. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 21: 47-57, 2007.
41. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 25: 312-321, 2000.
42. Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Cavalcanti RB, Wand H, Costagliola D, Walmsley S; Glitazone and Lipoatrophy Meta-Analysis Working Group. A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11: 39-50, 2010.
43. Rajagopalan R, Laitinen D, Dietz B. Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy. AIDS Care 20: 1197-1201, 2008.
44. Rosen CJ. Revisiting the rosiglitazone story - lessons learned. N Engl J Med 363: 803-806, 2010.
45. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 145: 397-406, 2006.
46. Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Romer V, Haider D, Pacini G, Ludvik B. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in HIV-positive patients on highly-active antiretroviral therapy (HAART). Horm Metab Res 41: 573-579, 2009.
47. Schonfeld G, Patterson BW, Yablonskiy DA, Tanoli TS, Averna M, Elias N, Yue P, Ackerman J. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 44: 470-478, 2003.
48. Silic A, Janez A, Tomazic J, Karner P, Vidmar L, Sharma P, Maticic M. Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. Croat Med J 48: 791-799, 2007.
49. Slama L, Lanoy E, Valantin MA, Bastard JP, Chermak A, Boutekatjirt A, William-Faltaos D, Billaud E, Molina JM, Capeau J, Costagliola D, Rozenbaum W. Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antivir Ther 13: 67-76, 2008.
50. Subramanian S, DeRosa MA, Bernal-Mizrachi C, Laffely N, Cade WT, Yarasheski KE, Cryer PE, Semenkovich CF. PPAR activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. Am J Physiol Endocrinol Metab 291: E1365-E1371, 2006.
51. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M, Yki-Järvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy - a randomized double-blind placebo-controlled study. Antivir Ther 8: 199-207, 2003.
52. Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamaki A, Funahashi T, Matsuzawa Y, Vidal H, Hamsten A, Yki-Jarvinen H. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 286: E941-E949, 2004.
53. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol 292: H1655-H1663, 2007.
54. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14: F63-F67, 2000.
55. Tien PC, Grunfeld C. What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 17: 27-32, 2004.
56. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92: 2506-2512, 2007.
57. Tungsiripat M, Bejjani DE, Rizk N, O'Riordan MA, Ross AC, Hileman C, Storer N, Harrill D, McComsey GA. Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS 24: 1291-1298, 2010.
58. van Wijk JP, de Koning EJ, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI. Comparison of rosiglitazone and met-formin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 143: 337-346, 2005.
59. Yarasheski KE, Tebas P, Claxton S, Marin D, Coleman T, Powderly WG, Semenkovich CF. Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. Am J Physiol Endocrinol Metab 285: E899-E905, 2003.